Investigation of Genetic Polymorphisms of Cytochrome P450 2C19 in Iranian Patients with Drug-Eluting Stents
,
Abstract
Background: Cytochrome P450 2C19 (CYP2C19) exhibits polymorphism, with about 21 known allelic variants. Notably, the *17 allele is associated with increased enzymatic activity, culminating in enhanced CYP2C19 activity and the ultra-rapid metabolizer (UM) phenotype. This genetic variation has a profound impact on an individual's response to a wide range of medications. The primary objective of this study was to ascertain the prevalence of the CYP2C19*17 allele among Iranian patients who have received drug-eluting stents.
Methods: This study was conducted to examine the genetic polymorphism of the CYP2C19 enzyme in 100 patients with drug-eluting stents (DESs) at Imam Hossein Hospital, Tehran, Iran. All participants were selected based on pre-defined inclusion criteria. Blood samples were obtained for DNA extraction, and CYP2C19 genotypes were subsequently analyzed through polymerase chain reaction (PCR) and gel electrophoresis.
Results: The *17 polymorphism was detected in 11% of the cohort. Of this group, 11 individuals were heterozygous carriers of the CYP2C19*17 allele, whereas the homozygous *17/*17 genotype was not observed in any participant.
Conclusion: Our findings demonstrate a low prevalence of the CYP2C19*17 allele and an absence of the homozygous *17/*17 genotype in the Iranian population. Despite its lower prevalence compared to other populations, the clinical implications of this allele are still considered highly significant.
Lanni C, Racchi M, Govoni S. Do we need pharmacogenetics to personalize antidepressant therapy? Cell Mol Life Sci. 2013;70(18):3327-40.
Dahl ML, Gunes A. Implications of inter-individual differences in clopidogrel metabolism, with focus on pharmacogenetics. Pharmaceuticals (Basel). 2010;3(4):782-94.
Marzinke MA, Breaud AR, Clarke W. The development and clinical validation of a turbulent-flow liquid chromatography–tandem mass spectrometric method for the rapid quantitation of docetaxel in serum. Clinica Chimica Acta. 2013;417:12-18.
Shin DJ, Kwon J, Park AR, Bae Y, Shin ES, Park S, et al. Association of CYP2C19* 2 and* 3 genetic variants with essential hypertension in Koreans. Yonsei Med J. 2012;53(6):1113-9.
Schork NJ, Fallin D, Lanchbury JS. Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet. 2000;58(4):250-64.
Lu J, Shang X, Zhong W, Xu Y, Shi R, Wang X. New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases. Acta Pharm Sin B. 2020;10(1):91-104.
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704-14.
Lee MS, Flammer AJ, Lerman LO, Lerman A. Personalized medicine in cardiovascular diseases. Korean Circ J. 2012;42(9):583-91.
Ko W, Tranbaugh R, Marmur JD, Supino PG, Borer JS. Myocardial revascularization in New York State: variations in the PCI-to-CABG ratio and their implications. J Am Heart Assoc. 2012;1(2):e001446.
Jagannathan R, Patel SA, Ali MK, Narayan KV. Global updates on cardiovascular disease mortality trends and attribution of traditional risk factors.Curr Diab Rep. 2019(7);44.
Schulz S, Sibbing D, Braun S, Morath T, Mehilli J, Massberg S, et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. Am Heart J. 2010;160(2):355-61.
Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet. 2001;358(9281):527-33.
Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. Jama. 2007;297(2):159-68.
Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171-5.
Yu L, Wang T, Bai H, Zhu W, Li Y, Wu J, et al. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.BMC Cardiovasc Disord. 2021;21:1-10.
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-75.
Shetkar SS, Ramakrishnan S, Seth S, Chandna P, Verma SK, Bhargava B, et al. CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease. Indian Heart J. 2014;66(1):16-24.
Subraja K, Dkhar S, Priyadharsini R, Ravindra B, Shewade D, Satheesh S, et al. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol. 2013;69(3):415-22.
Al-Jenoobi FI, Alkharfy KM, Alghamdi AM, Bagulb KM, Al-Mohizea AM, Al-Muhsen S, et al. CYP2C19 genetic polymorphism in Saudi Arabians. Basic Clin Pharmacol Toxicol. 2013;112(1):50-4.
Davidson S. Monitoring of Antiplatelet Therapy. Methods Mol Biol. 2023;2663:381-402.
Kassimis G, F Stavrou E, Alexopoulos D, Athanassiadou A. Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped? Curr Pharm Des. 2013;19(13):2489-95.
Mohammadi M, Hadjibabaie M, Khalili E, Ebrahimpour S. Association between cytochrome P450 2C19 gene polymorphisms and hematological malignancies in an Iranian population. Iranian Journal of Blood and Cancer. 2019;11(3):85-90.
Payan M, Rouini MR, Tajik N, Ghahremani MH, Tahvilian R. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population. DARU. 2014;22(1):81.
Ionova Y, Ashenhurst J, Zhan J, Nhan H, Kosinski C, Tamraz B,et al. CYP2C19 allele frequencies in over 2.2 million direct-to-consumer genetics research participants and the potential implication for prescriptions in a large health system. J Clin Transl Res. 2020;13(6):1298-1306.
Dehbozorgi M, Kamalidehghan B, Hosseini I, Dehghanfard Z, Sangtarash MH, Firoozi M, et al. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Rep. 2018;17(3):4195-202.
Hahn M, Roll SC. The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions. Pharmaceuticals (Basel). 2021;14(5):487.
Warlo EM, Arnesen H, Seljeflot I. A brief review on resistance to P2Y 12 receptor antagonism in coronary artery disease. Thromb J. 2019;17:11.
Anichavezhi D, Chakradhara Rao U, Shewade D, Krishnamoorthy R, Adithan C. Distribution of CYP2C19* 17 allele and genotypes in an Indian population. J Clin Pharm Ther. 2012;37(3):313-8.
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-13.
Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19* 17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 2008;65(3):437-9.
Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19* 17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83(2):322-7.
Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Droździk M. Effect of CYP2C19* 17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol. 2006;62(10):877-80.
Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19* 2, CYP2C19* 3, and CYP2C19* 17 alleles. J Clin Pharm Ther. 2010;35(6):697-703.
Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genomics. 2011;12:13.
Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19* 17 discovery: the case of Greece. Pharmacogenomics J. 2009;10(1):43-9.
Susleyici B, Ciftci C, Yurdakul S, Cevik M, Akdeniz CS, Canbolat IP, et al. Prevalence of CYP2C19 Polymorphisms in Clopidogrel Treated Turkish Patients: Preliminary Results, 2017. Curr Pharmacogenomics Person Med. 2021;18(2):116-22.
| Issue | Vol 13, No 3 (Summer 2025) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v13i3.20320 | |
| Keywords | ||
| Genetic Polymorphism CYP Cytochrome P450 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
